MA38491B1 - Dérivé dihydropyridazine-3,5-dione - Google Patents
Dérivé dihydropyridazine-3,5-dioneInfo
- Publication number
- MA38491B1 MA38491B1 MA38491A MA38491A MA38491B1 MA 38491 B1 MA38491 B1 MA 38491B1 MA 38491 A MA38491 A MA 38491A MA 38491 A MA38491 A MA 38491A MA 38491 B1 MA38491 B1 MA 38491B1
- Authority
- MA
- Morocco
- Prior art keywords
- dihydropyridazine
- dione derivative
- prophylactic
- salt
- derivative
- Prior art date
Links
- 239000003814 drug Substances 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 2
- 230000000069 prophylactic effect Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 108010092528 Phosphate Transport Proteins Proteins 0.000 abstract 1
- 102000016462 Phosphate Transport Proteins Human genes 0.000 abstract 1
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 201000005991 hyperphosphatemia Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne un dérivé dihydropyridazine-3,5-dione, un de ses sels et des solvates du dérivé et du sel. L'invention concerne également les éléments suivants, lesquels contiennent l'un quelconque desdits composés comme principe actif : un médicament, une composition de médicament, un inhibiteur de transporteur phosphate dépendant du sodium, et un agent prophylactique et/ou thérapeutique ainsi qu'une méthode prophylactique et/ou thérapeutique contre l'hyperphosphatémie, l'hyperparathyroïdisme secondaire et l'insuffisance rénale chronique.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013051082 | 2013-03-13 | ||
| PCT/JP2014/056778 WO2014142273A1 (fr) | 2013-03-13 | 2014-03-13 | Dérivé dihydropyridazine-3,5-dione |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA38491A1 MA38491A1 (fr) | 2016-12-30 |
| MA38491B1 true MA38491B1 (fr) | 2017-09-29 |
Family
ID=56119094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA38491A MA38491B1 (fr) | 2013-03-13 | 2014-03-13 | Dérivé dihydropyridazine-3,5-dione |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR095394A1 (fr) |
| MA (1) | MA38491B1 (fr) |
-
2014
- 2014-03-13 AR ARP140100938A patent/AR095394A1/es active IP Right Grant
- 2014-03-13 MA MA38491A patent/MA38491B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA38491A1 (fr) | 2016-12-30 |
| AR095394A1 (es) | 2015-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018502747A1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
| PH12015501940A1 (en) | Dihydropyridazine-3,5-dione derivative | |
| PH12018500041A1 (en) | Substituted aza compoounds as irak-4 inhibitors | |
| MA35861B1 (fr) | Inhibiteur de la kinase régulant les signaux de l'apoptose | |
| MD4659B1 (ro) | Polimorf al inhibitorilor SYK | |
| EA201590224A1 (ru) | Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы | |
| MX2015012427A (es) | Compuestos de morfolinona de acido heteroarilo como inhibidores mdm2 para el tratamiento de cancer. | |
| MX352672B (es) | Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer. | |
| EA201400412A1 (ru) | ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ | |
| MA38039A1 (fr) | Composés de céphem substitués en position 2 | |
| EA201691574A1 (ru) | Конденсированное бициклическое 2,4-диаминопиримидиновое производное в качестве двойного alk и fak ингибитора | |
| HK1205506A1 (en) | Protein kinase inhibitors | |
| MA39152B1 (fr) | Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine | |
| MA47736B1 (fr) | Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1 | |
| MX362896B (es) | Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cáncer. | |
| PH12014502492A1 (en) | Pyrazole compounds as sglt1 inhibitors | |
| TN2019000038A1 (en) | Triazolopyrazinone derivative useful as a human pde1 inhibitor | |
| UA110577C2 (uk) | Агент для боротьби з захворюваннями рослин, спосіб боротьби з захворюваннями рослин і продукт для боротьби з захворюваннями | |
| PH12018500433B1 (en) | Compound having effect of inhibiting platelet aggregation and salt thereof, and composition for preventing or treating thrombotic diseases, containing same | |
| MA38491A1 (fr) | Dérivé dihydropyridazine-3,5-dione | |
| EA201690797A1 (ru) | Новые соединения | |
| WO2013165898A3 (fr) | Compositions et procédés d'inhibition de résolvases | |
| WO2014149973A3 (fr) | Compositions et méthodes de traitement de maladies osseuses | |
| PH12013500498A1 (en) | Composition for improving brain function and method for improving brain function | |
| HK1250568A1 (en) | Human dosing of phosphatase inhibitor |